The therapeutic community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant efficacy in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a more substantial reduction in body mass and benefit metabolic markers, here part